In our study, we found that HER2-low expression was more common in HR+ tumors (HR+ group: 69.03%, HR- group: 57.81%), a result that seems to be basically similar to previous studies (19), i.e., HR hormone receptors tend to be more expressed in HER2-low expressing breast cancers. This evidence concerns the gene NR4A1 and breast cancer.